A marketing battle with an unusual twist is brewing between Allergan Inc.’s popular anti-wrinkle agent Botox and Ipsen/Medicis Pharmaceutical Corp.’s new-to-the-block Dysport: both sides are citing their REMS as a key competitive advantage.
The REMS (Risk Evaluation and Mitigation Strategy) program is turning out to be a weapon of choice because it gives...